Wednesday 17 April 2024
07:45
Prof Andrew Tutt
The detection and treatment of secondary cancer
With breast cancer touching the lives of so many people we know, yet so little known about recognising secondary cancer, we felt it essential that we highlight the critical importance of detecting the early signs. In numbers, there are currently 600,000 women in the UK who have survived 5+ years after primary breast cancer; less well known is that 20-30% of them will get incurable secondary cancer. Early diagnosis is pivotal in life expectancy and quality of life for this group.
Andrew is a Consultant Oncologist at the Breast Units of Guys’ and St Thomas’ and Royal Marsden NHS Foundation Trusts. He is a member of the St Gallen Early Breast Cancer International Consensus Panel, the Oxford Early Breast Cancer Trialists Cooperative Group (EBCTCG) and is Chair of CRUK Experimental Medicine Expert Review Panel. He is a member of ESMO Breast Cancer Guidelines Group and serves on the ESMO annual Scientific Committee meeting.
In addition, he is a Professor of Breast Oncology, Head of the Division of Breast Cancer Research and Director of the Breast Cancer Now Toby Robins Research Centre, at the Institute of Cancer Research in London (ICR), and a Professor of Clinical Oncology at King’s College London (KCL) where he is also the Director of the Breast Cancer Now Research Unit.
Consultant Oncologist and Professor of Breast Oncology
Andrew is a Consultant Oncologist at the Breast Units of Guys’ and St Thomas’ and Royal Marsden NHS Foundation Trusts. He is a member of the St Gallen Early Breast Cancer International Consensus Panel, the Oxford Early Breast Cancer Trialists Cooperative Group (EBCTCG) and is Chair of CRUK Experimental Medicine Expert Review Panel. He is a member of ESMO Breast Cancer Guidelines Group and serves on the ESMO annual Scientific Committee meeting.
In addition, he is a Professor of Breast Oncology, Head of the Division of Breast Cancer Research and Director of the Breast Cancer Now Toby Robins Research Centre, at the Institute of Cancer Research in London (ICR), and a Professor of Clinical Oncology at King’s College London (KCL) where he is also the Director of the Breast Cancer Now Research Unit.
